CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.

• アブストラクト	Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.
  ジャーナル名	Blood
  投稿日	2024/3/14
  投稿者	Elsallab, Magdi; Ellithi, Moataz; Lunning, Matthew A; D'Angelo, Christopher; Ma, Jihyun; Perales, Miguel-Angel; Frigault, Matthew; Maus, Marcela V
  組織名	Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.;Cellular Immunotherapy Program, Mass General Cancer Center, and Department of;Medicine, Harvard Medical School, Boston, MA.;Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University;of Nebraska Medical Center, Omaha, NE.;Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.;Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan;Kettering Cancer Center, New York, NY.;Department of Medicine, Weill Cornell Medical College, New York, NY.
  Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38483155/

  タグ:

  • FAERS

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date(投稿日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み